Is a complete KLRA research report available?

No complete published report is available for Kailera Therapeutics, Inc. (KLRA) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Kailera Therapeutics, Inc. (KLRA)

NASDAQ: KLRA · USD

$16.9

+0.14 (+0.8%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-30 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first KLRA analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	2.2B
Net income (ttm)	-209.8M
EPS (ttm)	-$7,006
Shares out	129.6M
Volume	526,524
Price target	$42.6	+152.4%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -209.8M
EPS (ttm): -$7,006
Market cap: 2.2B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All KLRA indicators

Market & fundamental data

Available fields

150

Groups with data

Currency

USD

Showing 150 of 150 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0002096997
Company name	Kailera Therapeutics, Inc.
Country	United States
Country code	US
Cusip	482931102
Employees	145
Enterprise value	$1.6B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2026-04-17
Isin	US4829311020
Last refreshed	2026-07-30
Market cap	$2.2B
Market cap category	Mid-Cap
Price	$16.88
Price currency	USD
Sector	Healthcare
Sector PE	45.63
Sector PE Fwd	24.38
Sic	2834
Symbol	KLRA
Tags	pharmaceuticals
Website	https://www.kailera.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-9.59%
FCF yield	-7.88%
P/B ratio	3.9x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-209.8M
Net Income Growth Years	0%
Profit Per Employee	$-1.4M
ROCE	-27.78

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$624.8M
Cash	$519.2M
Current Assets	$530.3M
Current Liabilities	$54.8M
Debt	$10.5M
Debt Equity	$0.02
Equity	$560.3M
Liabilities	$64.5M
Long Term Assets	$94.4M
Long Term Liabilities	$9.6M
Net Cash	$571.5M
Net Cash By Market Cap	$26.13
Net Debt Equity	$-1.02
Tangible Book Value	$-432.1M
Tangible Book Value Per Share	$-14,426

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	9.67
Net Working Capital	$-42.7M
Quick ratio	9.53
Working Capital	$475.5M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
50-day SMA	20.23
All Time High	28.23
All Time High Change	-40.2%
All Time High Date	2026-04-20
All Time Low	16.51
All Time Low Change	2.24%
All Time Low Date	2026-07-29
ATR	1.49
Beta1y	1.71
High	18.76
High52	28.23
High52 Date	2026-04-20
High52ch	-40.2%
Low	16.51
Low52	16.51
Low52 Date	2026-07-29
Low52ch	2.24%
Ma50ch	-16.57%
Premarket Change Percent	-0.24
Premarket Price	$16.7
Premarket Volume	149
RSI	34.87
RSI Monthly	0
RSI Weekly	0
Sharpe ratio	-2.02x
Sortino ratio	-2.56
Tr1m	-18.96%
Tr1w	-5.12%
Tr3m	-29.14%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	6
Analyst Count Top	3
Analyst Price Target Top	$57
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.72
Operating Income	$-222.5M
Price target	$42.6
Price Target Change	$152
Price Target Change Top	$238

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	58,399,992%
Float Percent	45.07%
Net Borrowing	100,000,000
Shares Insiders	0.03%
Shares Institutions	16.79%
Shares Out	129,565,608
Short Float	10.98%
Short Ratio	5.54
Short Shares	4.95

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-185.8M
Adjusted OCF	-183,675,000
Average Volume	608,432.65x
Bv Per Share	-14,425.5
CAPEX	$-2.1M
Ch1m	-18.96
Ch1w	-5.12
Ch3m	-29.14
Change	0.84%
Change From Open	1.32
Close	16.74
Days Gap	-0.48
Depreciation Amortization	348,000
Dollar Volume	8,887,725.1
Earnings Date	2026-08-23
Earnings Time	amc
EBIT	$-158.3M
EBITDA	$-158M
EPS	$-7,006
F Score	1
FCF	$-172.4M
FCF EV Yield	-10.67x
FCF Per Share	$-1.33
Financing CF	595,679,000
Fiscal Year End	December
Founded	2,024
Investing CF	-415,310,000
Ipr	5.5
Iprfo	-35.08
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-26
Last Report Date	2026-03-31
Last Split Type	Never
Ma20	19.36
Ma20ch	-12.82%
Net CF	10,050,000
Next Earnings Date	2026-08-23
Open	16.66
Optionable	No
Position In Range	16.44
Ppne	12,024,000
Pre Close	16.74
Price Date	2026-07-29
Relative Volume	0.87x
Share Based Comp	13,356,000
Us State	Massachusetts
Volume	526,524

Kailera Therapeutics, Inc. (KLRA)

Coverage state: Market snapshot only — no published research

Generate the first KLRA analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · KLRA

Valuation

Balance sheet

Trading

Next earnings

Sector percentile context

All KLRA indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on KLRA

Frequently asked questions